GLP-1 Diabetes Drugs Draw Weight-Loss Demand and Safety Scrutiny

Drugs developed for the treatment of type 2 diabetes or obesity-related conditions have stood out due to their weight-loss effects, while their possible side effects are also being discussed. Recently, the use of these weight-loss drugs has increased globally, and widespread sharing on social media and other digital platforms has also increased demand among people without diabetes. The World Health Organization published its first global guideline in October 2025 on the use of GLP-1 drugs for the treatment of obesity as a chronic and recurrent disease.

The best-known drug with the active ingredient semaglutide is Ozempic. Ozempic works by mimicking the effects of a hormone known as GLP-1 in the body. Through this mechanism, the drug increases insulin release from the pancreas, while also reducing glucose production in the liver and slowing down stomach emptying. Like Ozempic, Mounjaro is also a drug approved by the U.S. Food and Drug Administration for type 2 diabetes treatment. It targets both GIP and GLP-1 receptors and has a dual mechanism of action. Another drug with the same active ingredient and available in higher-dose options in the U.S. is Wegovy, which is also available in tablet form.

These medications are primarily prescribed for long-term blood sugar control in patients with type 2 diabetes. Treatment typically starts with a low dose, which is gradually increased depending on patient tolerance. One of the effects of the drug is appetite suppression. Due to slower stomach emptying and prolonged feelings of fullness, users tend to consume fewer calories, which can lead to weight loss in many patients.

Clinical trials and data from approval processes show that semaglutide-based treatments are effective and generally safe for diabetic patients. However, as with all medications, side effects can occur. The most common side effects are related to the digestive system, including nausea, vomiting, diarrhea and constipation, especially during the early stages of treatment. Less common but more serious side effects include pancreatitis, gallbladder disease and impaired kidney function. Additionally, animal studies have shown potential risks related to the thyroid gland, so use may be restricted in individuals with certain thyroid conditions.

Some users who experience rapid weight loss may also report loss of muscle mass, associated weakness and rapid weight regain after stopping the drug. These effects are more pronounced when the medication is used without medical necessity or without proper dietary management. The safety of these drugs depends on their intended use and whether they are taken under medical supervision, and because these drugs have strong effects on metabolism, the FDA requires medical supervision during their use.

The guideline states that GLP-1 treatments for obesity can be used in adults, excluding pregnant women, but emphasizes that long-term safety data is still limited. It also stresses that medication alone is not sufficient and must be combined with healthy eating, physical activity and professional support. The guideline further highlights high costs and unequal access, emphasizing that medication alone will not solve the obesity problem.

The link between excess body fat and type 2 diabetes is also about how fat cells behave. Excess weight is tightly linked with development and worsening of insulin resistance, and when the body becomes increasingly resistant to insulin, type 2 diabetes can become more difficult to manage. Visceral fat triggers inflammation, spillover fat impacts the liver and pancreas, and hormone resistance can make people feel constantly hungry even when the body has plenty of stored energy.

Type 2 diabetes also creates hurdles that make losing weight and keeping it off challenging. When blood sugar is high, people may feel hungrier than usual or have stronger cravings. Fatigue can make it difficult to find the energy to exercise, nerve pain can make movement uncomfortable, and many also avoid activity due to a fear of low blood sugar. Diabetes medications like insulin, sulfonylureas, thiazolidinediones, and meglitinides effectively lower sugar but often cause weight gain.

Because they target weight and blood sugar at the same time, these medications are an excellent option for people who need to improve both their A1C test results and their weight to stay healthy. Beyond the scale, they also offer long-term protection for the heart and kidneys. Wegovy, in addition to weight loss purposes, has also received FDA approval for benefits related to heart health and preventing fatty liver disease.